Since November 2010, I have been following Advanced Cell Technology’s (ACT) quest to implement successful clinical trials for macular eye disease, using human embryonic stem cells. ACT’s U.S. and European Phase I/II clinical trials each involve a total of 12 patients, in groups of three (also called cohorts). The first group/cohort received a dosage of … Continued
Since November 2010, I have been following Advanced Cell Technology’s (ACT) quest to implement successful clinical trials for macular eye disease, using human embryonic stem cells. Here is an update of ACT’s progress to date: Moorfields Eye Hospital On July 27, 2012, ACT announced the treatment of the third patient in its European Phase I/II … Continued
From a press release from the National Institutes of Health (NIH): The National Institutes of Health has created a new website, NIH Clinical Research Trials and You, to help people learn more about clinical trials, why they matter, and how to participate. From the first cure of a solid tumor with chemotherapy to the use … Continued
As our readers know, I am committed to investigating and reporting the latest information about macular degeneration, including ongoing research and clinical trial results; thus I am extremely pleased to note that the New York Times is presenting a three-pronged series on macular diseases and disorders. In the latest installment of the New York Times … Continued
On Tuesday, July 12, 2011, Advanced Cell Technology (ACT) announced the treatment of the first two patients in its two Phase I/II clinical trials for Stargardt’s disease and dry macular degeneration (AMD), using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells. The procedures were carried out by principal investigator Steven Schwartz, M.D., … Continued
Once again, Advanced Cell Technology (ACT) is in the news with yet another potential advance in stem cell therapy for macular disease, in this case for the dry form of macular degeneration. To better understand this latest development, here is background information from my prior blog post about ACT’s initial stem cell therapy trial for … Continued
Wow. This is surprising – and groundbreaking – news. First, here’s some background: In August of this year, The Wall Street Journal reported that Judge Royce Lamberth of U.S. District Court in Washington, D.C. had issued a preliminary injunction against federal funding for human embryonic stem cell research. The judge stated that federal funding violated … Continued